Seilern Investment Management Ltd Makes New $109.49 Million Investment in Edwards Lifesciences Co. (NYSE:EW)

Seilern Investment Management Ltd bought a new stake in Edwards Lifesciences Co. (NYSE:EW) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 1,478,989 shares of the medical research company’s stock, valued at approximately $109,490,000. Edwards Lifesciences accounts for approximately 6.2% of Seilern Investment Management Ltd’s investment portfolio, making the stock its 8th largest holding.

Several other large investors have also modified their holdings of the stock. Dimensional Fund Advisors LP lifted its position in Edwards Lifesciences by 18.6% in the second quarter. Dimensional Fund Advisors LP now owns 1,399,329 shares of the medical research company’s stock valued at $129,271,000 after purchasing an additional 219,486 shares during the period. Edgestream Partners L.P. acquired a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $438,000. Brighton Jones LLC boosted its stake in shares of Edwards Lifesciences by 10.0% in the second quarter. Brighton Jones LLC now owns 3,742 shares of the medical research company’s stock valued at $346,000 after buying an additional 339 shares in the last quarter. Benjamin F. Edwards & Company Inc. grew its holdings in Edwards Lifesciences by 29.8% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 13,295 shares of the medical research company’s stock worth $1,228,000 after acquiring an additional 3,049 shares during the period. Finally, AE Wealth Management LLC raised its position in Edwards Lifesciences by 14.8% in the second quarter. AE Wealth Management LLC now owns 4,618 shares of the medical research company’s stock worth $427,000 after acquiring an additional 594 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

NYSE EW opened at $69.77 on Monday. The business’s 50-day moving average price is $72.06 and its 200 day moving average price is $71.32. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a market capitalization of $41.15 billion, a PE ratio of 10.07, a price-to-earnings-growth ratio of 3.77 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same period in the prior year, the firm posted $0.59 EPS. The company’s revenue was up 8.9% on a year-over-year basis. On average, research analysts predict that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In related news, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 33,000 shares of company stock worth $2,195,180 in the last quarter. 1.27% of the stock is owned by insiders.

Analyst Ratings Changes

Several brokerages have commented on EW. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $82.00 to $90.00 in a research report on Monday, December 16th. Piper Sandler lowered their target price on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. The Goldman Sachs Group lifted their price target on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, December 5th. JPMorgan Chase & Co. upped their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Finally, Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research report on Monday, October 28th. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $78.48.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.